Evidence map›Paper›PMID 38260526›Full record

ArticleResearch square2024

Duration of Endocrine Treatment for DCIS impacts second events: Insights from a large cohort of cases at two academic medical centers.

Thomas O'Keefe, Christina Yau, Emma Iaconetti, Eliza Jeong, Case Brabham, Paul Kim, Joseph McGuire, Ann Griffin, Anne Wallace, Laura Esserman and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Thomas O'KeefeDepartment of Surgery, University of California, San Diego.
Christina YauDepartment of Surgery, University of California, San Francisco, CA.ORCID 0000-0002-1937-0859
Emma IaconettiDepartment of Surgery, University of California, San Francisco, CA.
Eliza JeongMoores Cancer Center, Division of Biomedical Informatics, UCSD School of Medicine University of California, San Diego, La Jolla, CA.
Case BrabhamDepartment of Surgery, University of California, San Francisco, CA.
Paul KimDepartment of Surgery, University of California, San Francisco, CA.
Joseph McGuireUCSF Helen Diller Family Comprehensive Cancer Center.
Ann GriffinUCSF Helen Diller Family Comprehensive Cancer Center.ORCID 0000-0003-0837-6515
Anne WallaceDepartment of Surgery, University of California, San Diego.
Laura EssermanDepartment of Surgery, University of California, San Francisco, CA.ORCID 0000-0001-9202-4568
Olivier HarismendyMoores Cancer Center, Division of Biomedical Informatics, UCSD School of Medicine University of California, San Diego, La Jolla, CA.
Gillian HirstDepartment of Surgery, University of California, San Francisco, CA.ORCID 0000-0002-4502-0035
University of California, San Francisco · US

Funding

Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancersU01CA196406 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOROWSKY, ALEXANDER D, ESSERMAN, LAURA J · 2015 to 2020
$5.8M
NCI NIH HHS U01 CA196406
6 · The paper itself

Abstract

Ductal carcinoma in situ (DCIS) incidence has risen rapidly with the introduction of screening mammography, yet it is unclear who benefits from both the amount and type of adjuvant treatment (radiation therapy, (RT), endocrine therapy (ET)) versus what constitutes over-treatment. Our goal was to identify the effects of adjuvant RT, or ET+/- RT versus breast conservation surgery (BCS) alone in a large multi-center registry of retrospective DCIS cases (N = 1,916) with median follow up of 8.2 years. We show that patients with DCIS who took less than 2 years of adjuvant ET alone have a similar second event rate as BCS. However, patients who took more than 2 years of ET show a significantly reduced second event rate, similar to those who received either RT or combined ET+RT, which was independent of age, tumor size, grade, or period of diagnosis. This highlights the importance of ET duration for risk reduction.

Indexed as

DCISendocrine therapyendocrine therapy durationtreatment outcome

Identifiers

PMID38260526
PMCPMC10802747
OpenAlexW4390745956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.